Exploration of the Clinical Efficacy of Anlotinib Combined With Docetaxel in Lung Cancer

Objectives The purpose of this article is to explore the clinical efficacy of anlotinib combined with docetaxel in lung cancer. Methods A retrospective analysis was conducted on 100 lung cancer patients admitted to our hospital from March 2020 to February 2025. Among them, 50 patients received treatment with docetaxel (the control group), and 50 patients received treatment with anlotinib combined with docetaxel (the observation group). The clinical efficacy, quality of life, and adverse reactions of the two groups were compared. Results After treatment, in the control group, there was 1 case of complete response, 13 cases of partial response, 17 cases of stable disease, and 19 cases of progressive disease; in the observation group, there were 2 cases of complete response, 18 cases of partial response, 20 cases of stable disease, and 10 cases of progressive disease. The overall therapeutic effect of the observation group was better than that of the control group. After the treatment, there were no significant differences in the scores of social function, role function and cognitive function between the two groups. However, the scores of emotional function, physical function and general health of the observation group were significantly higher than those of the control group. Moreover, there was no significant difference in the incidence of adverse reactions between the two groups. Conclusions The treatment combining anlotinib with docetaxel is beneficial for enhancing the clinical efficacy of lung cancer patients, improving their quality of life, and does not increase the risk of adverse reactions.